Visiting Scientist, Acting Head of Medicinal Chemistry completed his Ph.D studies in Synthetic Organic Chemistry at Pennsylvania State University, USA in 1987 working under Professor Steve Weinreb in the area of Alkaloid total Synthesis and his postdoctoral research at SUNY Albany under Professor Frank Hauser in Anthracycline total synthesis. After working at Sterling Winthrop and Affymax Pharmaceuticals he joined Pfizer Pharmaceuticals in 1996 as a Medicinal Chemist in Groton, Connecticut.
Since joining Pfizer, he has worked in multiple therapeutic areas, including Inflammation and Immunology, Oncology, Neuroscience and Anti Infectives. He has made significant contributions to a number of projects and was a member of the team that discovered Xeljanz® an orally active Janus Kinase 3 Inhibitor for Rheumatoid Arthritis. He is a recipient of ACS Heroes of Chemistry and ACS Team Innovation Awards for the contribution to discovery of Xeljanz®. He has led many project teams which helped drive HTS hits to chemical probes and clinical candidates in the area of Neuroscience and Antiinfectives. Most recently he worked in the area of Antibody drug conjugates for the treatment of Cancer and contributed to the discovery of clinical candidates. Currently, Dr. Subbu is a visiting scientist in the INCPM, and is working closely with Dr. Barr’s HTS group until he returns to Pfizer in the spring of 2019. Dr. Subbu is an author of 40 scientific publications and an inventor on over 40 patents and patent applications.
Completed her Ph.D studies in Computational Chemistry at Weizmann Institute of Science, Rehovot, Israel in 2005 working under Prof. Ephraim Katchalski- Katzir and Dr. Miriam Eisenstein in the area of Molecular Recognition in Biology: Combining Biological Information and Bioinformatics with Computational Docking.
She has seven years of industry experience in two pharmaceutical startup companies driving projects from idea through discovery and development up to the clinical phase. Since joining pharma industry, she has worked in multiple therapeutic areas, including Cancer, Metabolic Diseases, Inflammation, and Immunology in several GPCR, ion-channel and kinase programs. She has made significant contributions to the discovery of several compounds resulting in therapeutic drug candidates. Currently, Dr. Ben-Zeev is the leading computational chemist and chemoinformatician scientist in the G-INCPM, and is working closely with Dr. Subramanyam’s Medicinal Chemistry group and Dr. Barr’s HTS group. Dr. Ben-Zeev is an author of 17 scientific publications and an inventor on 8 patents.
Khriesto A. Shurrush graduated Cum Laude from the University of Nebraska at Kearney in 2007 with a B.S degree in chemistry. He then continued his graduate studies under the guidance of Professor Arun K. Ghosh at Purdue University, were he developed synthetic strategies for the synthesis of aldol products by a non conventional aldol route and poly substituted furans. He also completed the total synthesis of tetrahydrolipstatin (Orlistat) used for the treatment of obesity and (+)-Neopeltolide a nano molar inhibitor of tumor cell proliferation.
Upon completion of his graduate studies in 2013 he returned to Israel to start his post-doctoral studies under the supervision of Professor Ilan Marek at the Technion-Israel Institute of Technology. Were he focused on the discovery of new chemical transformations using organo metallic reagents and there applications in enantioselective synthesis.
Nicolas Germain obtained a Bachelor in chemistry at the Université of Franche-Comté. He then moved to the University of Strasbourg (Master thesis supervisor: Prof. P. Pale) to complete a Ms.C. During his masters studies, Nicolas spent five months at the university of Osaka (internship supervisor: Prof. K. Mashima) and additional two months in the same lab before starting his doctoral studies at the University of Geneva (PhD advisor: Prof. A. Alexakis). At the University of Geneva, Nicolas’ work focused on Copper-Catalyzed Asymmetric Conjugate Additions of Grignard Reagents and Electrophilic Trappings of Mg-Enolates where he received his PhD in August of 2014. He then moved to Heidelberg for an industrial postdoc at CaRLa (Catalysis Research Laboratory, University of Heidelberg - BASF). In 2016 Nicolas joined the lab of Ilan Marek at the Israel Institute of Technology (Technion) as a Post Doctoral Student where he focused on new methodologies involving transition metals. His research interests range from organic chemistry to organometallic chemistry and main group chemistry. In July 2017, Nicolas joined the Medicinal Chemistry Team at the G-INCPM.